Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC, Scheper RJ, Giaccone G, de Gruijl TD. van Cruijsen H, et al. Among authors: van den eertwegh aj. Clin Dev Immunol. 2007;2007:17315. doi: 10.1155/2007/17315. Clin Dev Immunol. 2007. PMID: 18320010 Free PMC article. Clinical Trial.
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. van Cruijsen H, et al. Among authors: van den eertwegh aj, van der veldt aa. Clin Cancer Res. 2008 Sep 15;14(18):5884-92. doi: 10.1158/1078-0432.CCR-08-0656. Clin Cancer Res. 2008. PMID: 18794101
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VW, Broxterman HJ. Vroling L, et al. Among authors: van cruijsen h, van den eertwegh aj, van hinsbergh vw, van der veldt aa. Angiogenesis. 2009;12(1):69-79. doi: 10.1007/s10456-009-9133-9. Epub 2009 Feb 11. Angiogenesis. 2009. PMID: 19212818 Free article.
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.
van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. van Cruijsen H, et al. Among authors: van der valk p. BMC Cancer. 2009 Jun 11;9:180. doi: 10.1186/1471-2407-9-180. BMC Cancer. 2009. PMID: 19519895 Free PMC article.
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G. van Cruijsen H, et al. Among authors: van herpen cm. Eur J Cancer. 2010 Mar;46(5):901-11. doi: 10.1016/j.ejca.2009.12.023. Epub 2010 Jan 12. Eur J Cancer. 2010. PMID: 20061136 Clinical Trial.
27 results